110th Congress

Pediatric Research Hearing

The House Energy and Commerce Subcommittee on Health (Representative Frank Pallone [D-NJ], Chairman) held a hearing on the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA). Both programs are due to be reauthorized this year. The BPCA is administered by both FDA and NICHD, whereas PREA is strictly an FDA responsibility. The Subcommittee heard testimony from government and non-government witnesses about the current status of programs implemented under these statutes, as well as issues related to pediatric medical devices. Dr. Donald Mattison, Chief, Obstetric and Pediatric Pharmacology Branch, NICHD, and Dr. Sandra Kweder, Deputy Director, Office of New Drugs, Center For Drug Evaluation and Research, FDA, testified.

Testimony: Dr. Donald Mattison, Chief, Obstetric and Pediatric Pharmacology Branch, NICHD

Testimony: Dr. Sandra Kweder, Deputy Director, Office of New Drugs, Center For Drug Evaluation and Research, FDA